Research progress on carcinogenic factors and personalized treatment of oral cancer
Xu K., Yang Q., Chen W., Li Z., Wu Y., Ren F.
Narrative Review, published in Discov Oncol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Discov Oncol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41350795
- PMCID
- PMC12796093
- DOI
- 10.1007/s12672-025-04222-3
Abstract (original English)
Oral cancer, particularly oral squamous cell carcinoma (OSCC), represents a significant global health burden, with notably high incidence in regions such as South and Southeast Asia. In China, both the incidence and mortality of oral cancer have been steadily rising, posing a growing threat to public health. Despite the identification of major risk factors—including tobacco use, alcohol consumption, betel quid chewing, and high-risk human papillomavirus (HPV) infection—the disease often remains asymptomatic in its early stages, leading to delayed diagnosis and poor prognosis. These clinical challenges are closely linked to the complex molecular pathogenesis of OSCC, involving genetic alterations, epigenetic dysregulation, tumor microenvironment remodeling, and immune evasion. Recent advances in multi-omics profiling, liquid biopsy, and immunotherapeutic strategies offer promising avenues for early detection, accurate staging, and personalized treatment. This review synthesizes cutting-edge research from both domestic and international scholars, focusing on the interplay between carcinogenic exposures, molecular mechanisms, and emerging therapeutic paradigms, thereby providing a comprehensive reference for future studies in oral cancer prevention and precision oncology.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.